Cargando…
SAT460 Higher TSH Receptor Antibody At Diagnosis And Younger Age Predict Recurrence of Graves' Thyrotoxicosis After Thionamide Withdrawal At 10 Years
Disclosure: F.W. Gibb: None. N. Tun: None. Background: Anti-thyroid drug (ATD) therapy in Graves’ disease is generally accepted to be a safe and effective means of restoring euthyroidism. Treatment is typically administered for 12 to 18 months followed by cessation subject to certain conditions such...
Autores principales: | Wilson Gibb, Fraser, Nyo Tun, Nyo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553580/ http://dx.doi.org/10.1210/jendso/bvad114.1934 |
Ejemplares similares
-
The Thionamide Paradox: Thyrotoxicosis With Neutropenia as Initial Presentation of Grave’s Disease
por: Celis, Valentina, et al.
Publicado: (2021) -
SAT488 Wolff-Chaikoff’s Revenge: There-and-Back Again Graves Thyrotoxicosis
por: Akofu, Anota, et al.
Publicado: (2023) -
FRI555 A Misdiagnosis Of TSH-secreting Adenoma With Thyrotoxicosis In A Patient With Graves’ Disease
por: Huynh, James, et al.
Publicado: (2023) -
SAT-463 Thyrotoxicosis from Nivolumab in a Patient with Preexisting Graves’ Disease
por: Polavarapu, Preethi, et al.
Publicado: (2020) -
SAT-410 Long Term Evaluation of TSH Receptor Antibodies and Thyroid Stimulating Immunoglobulin After Radioiodine Therapy for Thyrotoxicosis
por: Marui, Suemi, et al.
Publicado: (2020)